Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
53 studies found for:    canakinumab
Show Display Options
Rank Status Study
1 Completed Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Conditions: Type 1 Diabetes;   Preservation of Insulin Secretion;   Newly Diagnosed Type 1 Diabetes;   Canakinumab in Type 1 Diabetes
Intervention: Drug: canakinumab (anti IL-1beta)
2 Not yet recruiting An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Condition: Systemic Juvenile Idiopathic Arthritis
Interventions: Drug: Canakinumab - Cohort 1;   Drug: Canakinumab - Cohort 2
3 Completed Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Canakinumab
4 Completed
Has Results
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Condition: Acute Gout
Interventions: Drug: Canakinumab;   Drug: Triamcinolone acetonide
5 Recruiting Canakinumab for Treatment of Adult Onset Still's Disease
Condition: Adult-Onset Still´s Disease
Interventions: Drug: Canakinumab;   Drug: Placebo
6 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
7 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
8 Completed
Has Results
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe;   Drug: Canakinumab lyophilized powder;   Drug: Triamcinolone Acetonide;   Drug: Placebo
9 Completed
Has Results
Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy
Condition: Gout
Interventions: Drug: Canakinumab 25 mg;   Drug: Canakinumab 50 mg;   Drug: Canakinumab 100 mg;   Drug: Canakinumab 200 mg;   Drug: Canakinumab 300 mg;   Drug: Canakinumab repeated every 4 week (q4wk);   Drug: Colchicine;   Drug: Allopurinol;   Drug: Placebo Matching Canakinumab;   Drug: Placebo Matching Colchicine
10 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
11 Recruiting An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: Canakinumab
12 Active, not recruiting Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Condition: Schnitzler Syndrome
Interventions: Drug: Canakinumab;   Drug: Placebo
13 Completed
Has Results
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
Condition: Osteoarthritis
Interventions: Biological: Canakinumab;   Drug: Placebo to canakinumab;   Drug: Naproxen;   Drug: Placebo to Naproxen
14 Completed Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever
Intervention: Drug: Canakinumab
15 Not yet recruiting ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
Condition: Systemic Juvenile Idiopathic Arthritis (SJIA)
Intervention: Drug: ACZ885 150 mg (Canakinumab)
16 Completed Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
17 Completed Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
Condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
Intervention: Drug: Canakinumab
18 Completed
Has Results
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Conditions: Type 2 Diabetes Mellitus;   Impaired Glucose Tolerance
Interventions: Drug: Canakinumab 150 mg;   Drug: Placebo to Canakinumab
19 Completed
Has Results
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
Condition: Arthritis, Gouty
Interventions: Biological: canakinumab;   Drug: dexamethasone;   Other: placebo matching canakinumab;   Other: placebo matching dexamethasone
20 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years